User Image Cart Icon 0 Search Image

BCL-2

  1. 225Ac-Cd33 Radioimmunotherapy Potently Increases The Sensitivity Of Resistant Acute Myeloid Leukemia Lines To The Bcl-2 Inhibitor Venetoclax By Mediating A …
  2. 613 Poster Gx15-070, A Small Molecule Bcl-2 Family Inhibitor, Induces Apoptosis And Enhances Cisplatin-Induced Apoptosis In Non-Small Cell Lung Cancer …
  3. 8-Chrysoeriol, As A Potential Bcl-2 Inhibitor Triggers Apoptosis Of Sw1990 Pancreatic Cancer Cells
  4. A Functionally Improved Locked Nucleic Acid Antisense Oligonucleotide Inhibits Bcl-2 And Bcl-Xl Expression And Facilitates Tumor Cell Apoptosis
  5. A Literature Review Of The Patent Publications On Venetoclax–A Selective Bcl-2 Inhibitor: Discovering The Therapeutic Potential Of A Novel Chemotherapeutic Agent
  6. A Novel Bcl-2 Inhibitor, Bm-1197, Induces Apoptosis In Malignant Lymphoma Cells Through The Endogenous Apoptotic Pathway
  7. A Novel Bcl-2 Small Molecule Inhibitor 4-(3-Methoxy-Phenylsulfannyl)-7-Nitro-Benzofurazan-3-Oxide (Mnb)-Induced Apoptosis In Leukemia Cells
  8. A Novel Small Molecule Inhibitor Targeted At Bcl-2
  9. A Phase 1B/2 Clinical Study Of Targeted Idh1 Inhibition With Ivosidenib, In Combination With The Bcl-2 Inhibitor Venetoclax, For Patients With Idh1-Mutated (Midh1) …
  10. A Phase I Study Of The Pan Bcl-2 Family Inhibitor Obatoclax Mesylate In Patients With Advanced Hematologic Malignancies
  11. A Phase I Trial Of The Small Molecule Pan-Bcl-2 Inhibitor Obatoclax (Gx15–070) In Combination With Docetaxel In Patients With Relapsed Non-Small Cell Lung Cancer …
  12. A Phase Ib/Ii Study Of The Bcl-2 Inhibitor Venetoclax In Combination With Standard Intensive Aml Induction/Consolidation Therapy With Flag-Ida In Patients With …
  13. A Safety And Schedule Seeking Trial Of Bcl-2 Inhibitor Obatoclax In Previously Untreated Older Patients With Acute Myeloid Leukemia (Aml)
  14. A Small Molecule Inhibitor Of Bcl-2, Ha14-1, Also Inhibits Ceramide Glucosyltransferase
  15. A Small Molecule Pan-Bcl-2 Family Inhibitor, Gx15-070, Induces Apoptosis And Enhances Cisplatin-Induced Apoptosis In Non-Small Cell Lung Cancer Cells
  16. A64 Cells Run A-Muc: Mucin Biology In The Lung: A Small Molecule Bcl-2 Inhibitor Switches Il-13 To A Cell Death Inducer For Allergen-Induced Metaplastic …
  17. Aberrantly Expressed Fra-1 By Il-6/Stat3 Transactivation Promotes Colorectal Cancer Aggressiveness Through Epithelial–Mesenchymal Transition
  18. Absorption, Metabolism, And Excretion Of A Novel Bcl-2 Inhibitor Venetoclax In Humans
  19. Abstract A245: Combination Of The Glycoengineered Type Ii Cd20 Antibody Obinutuzumab (Ga101), And The Novel Bcl-2 Selective Inhibitor, Abt-199 (Gdc-0199) …
  20. Abstract A30: Inhibition Of Pmca4 As A Strategy To Increase The Effectiveness Of Bcl-2 Inhibitor-Mediated Cell Death In Breast Cancer Cells.
  21. Abstract A77: Repression Of Mtorc1 Activity In Notch1 Mutant T-All Results In Sensitivity To The Bcl-2 Inhibitor Abt-263
  22. Abstract B4: A Microrna Screen To Identify Modulators Of Sensitivity To Bcl-2 Inhibitor Abt-263
  23. Abstract Ct069: Correlative Biomarkers Of Clinical Activity Of The Bcl-2 Inhibitor, Venetoclax (Abt-199/Gdc-0199), In Acute Myeloid Leukemia Patients
  24. Abstract Lb-212: Mcl-1 And Fbw7 Control A Dominant Survival Pathway Underlying Hdac And Bcl-2 Inhibitor Synergy In Squamous Cell Carcinoma.
  25. Abstract Lb-72: An Immunoassay Detecting Bcl-2: Bim And Mcl-1: Bim Complexes In The Phase 1 Monotherapy Study Of The Bcl-2 Inhibitor, Abt-199/Gdc-0199, In …
  26. Abstract Pd1-06: A Phase 1B Dose-Escalation And Expansion Study Of The Bcl-2 Inhibitor Venetoclax Combined With Tamoxifen In Er And Bcl-2–Positive Metastatic …
  27. Abstract# 3990: The Pan-Bcl-2 Family Inhibitor Abt-737 Synergizes With Dna Damaging Agents By Enhancing Apoptosis In Acute Lymphoblastic Leukemia Cells
  28. Abt-199, A Potent And Selective Bcl-2 Inhibitor, Achieves Antitumor Activity While Sparing Platelets
  29. Abt-737, An Inhibitor Of Bcl-2 Family Proteins, Is A Potent Inducer Of Apoptosis In Multiple Myeloma Cells
  30. Abt-737: A Small Molecule Inhibitor Of Bcl-2 With Dramatic Anti-Tumor Activity In Xenograft Models Of Small Cell Lung Cancer
  31. Abt‐199 (Venetoclax), A Bh3‐Mimetic Bcl‐2 Inhibitor, Does Not Cause Ca2+‐Signalling Dysregulation Or Toxicity In Pancreatic Acinar Cells
  32. Abt‐199 Selectively Inhibits Bcl-2 But Not Bcl-2 L 1 And Efficiently Induces Apoptosis Of Chronic Lymphocytic Leukaemic Cells But Not Platelets
  33. Acquisition Of Resistance To Trastuzumab In Gastric Cancer Cells Is Associated With Activation Of Il-6/Stat3/Jagged-1/Notch Positive Feedback Loop
  34. Activation Of Stat3 In Human Gastric Cancer Cells Via Interleukin (Il)-6-Type Cytokine Signaling Correlates With Clinical Implications
  35. Activity Of Vincristine, L-Asparaginase, And Dexamethasone Against Acute Lymphoblastic Leukemia Was Enhanced By The Bcl-2 Inhibitor Abt-737 In Vitro And In Vivo
  36. An Anti-Apoptotic Bcl-2 Family Protein Index Predicts The Response Of Leukemic Cells To The Pan-Bcl-2 Inhibitor S1.
  37. An Efficient Synthesis Of Abt-263, A Novel Inhibitor Of Antiapoptotic Bcl-2 Proteins
  38. An Inhibitor Of Bcl-2 Family Proteins Induces Regression Of Solid Tumours
  39. Anti-Allergic And Anti-Inflammatory Effects Of The Bcl-2 Inhibitor Abt-737 On Experimental Allergic Rhinitis Models
  40. Antiangiogenic Effect Of Tw37, A Small-Molecule Inhibitor Of Bcl-2
  41. Anticancer Effect Of Icaritin Inhibits Cell Growth Of Colon Cancer Through Reactive Oxygen Species, Bcl‑2 And Cyclin D1/E Signaling
  42. Antitumor Effects Of Sorafenib, Bevacizumab And Cetuximab As Single Agents Or In Combination With An Mek, Mtor Or Bcl-2 Inhibitor, In A Snu-398 Human …
  43. Apogossypolone, A Small-Molecule Inhibitor Of Bcl-2, Induces Radiosensitization Of Nasopharyngeal Carcinoma Cells By Stimulating Autophagy
  44. Apoptosis And Cell Cycle Arrest In Human Hepatocellular Carcinoma Cells And Enhance Chemosensitivity To Paclitaxel, Docetaxel, Doxorubicin And The Bcl-2 Inhibitor …
  45. Apoptosis And Cell Cycle Arrest In Human Hepatocellular Carcinoma Cells And Enhance Chemosensitivity To Paclitaxel, Docetaxel, Doxorubicin And The Bcl–2 Inhibitor …
  46. Apoptosis-Based Treatment Of Glioblastomas With Abt-737, A Novel Small Molecule Inhibitor Of Bcl-2 Family Proteins
  47. Arsenic Trioxide Synergistically Enhances The Antileukemia Activity Of Bcl-2 Inhibitor Abt-199 In Acute Myeloid Leukemia
  48. Aspirin Induces Apoptosis Through The Blockade Of Il-6-Stat3 Signaling Pathway In Human Glioblastoma A172 Cells
  49. Aspirin Promotes Apoptosis In A Murine Model Of Colorectal Cancer By Mechanisms Involving Downregulation Of Il-6–Stat3 Signaling Pathway
  50. At-101, A Pan-Bcl-2 Inhibitor, Leads To Radiosensitization Of Non-Small Cell Lung Cancer
  51. Autocrine Il-6-Induced Stat3 Activation Contributes To The Pathogenesis Of Lung Adenocarcinoma And Malignant Pleural Effusion
  52. Autophagy Eliminates Er Membrane Reorganization Induced By Bcl-2 Inhibitor In Hela Cells
  53. Autophagy Inhibition Enhances Pan-Bcl-2 Inhibitor At-101-Induced Apoptosis In Non-Small Cell Lung Cancer.
  54. Bcl-2 Family Regulation By The 20S Proteasome Inhibitor Bortezomib
  55. Bcl-2 Gene Silencing By Rna Interference Inhibits The Growth Of The Human Gallbladder Carcinoma Cell Line Gbc-Sd In Vitro And In Vivo
  56. Bcl-2 Inhibitor Abt-737 Enhances The Cisplatin-Induced Apoptosis In Breast Cancer T47D Cells
  57. Bcl-2 Inhibitor Ha14-1 And Genistein Together Adeptly Down Regulated Survival Factors And Activated Cysteine Proteases For Apoptosis In Human Malignant …
  58. Bcl-2 Inhibitor Scaffolds That Are Preorganized Along An Axis Of Chirality; The Effect Of Atropisomerism On Protein Binding
  59. Bcl-2 Inhibitor Uploaded Upconversion Nanophotosensitizers To Overcome The Photodynamic Therapy Resistance Of Cancer Through Adjuvant Intervention Strategy
  60. Bcl-2 Inhibitor Venetoclax Enhances Temozolomide Sensitivity In Aml
  61. Bcl-2 Selective Inhibitor Abt-199 Primes Rhabdomyosarcoma Cells To Histone Deacetylase Inhibitor-Induced Apoptosis
  62. Bcl‐2 Inhibitors Enhance Fgfr Inhibitor‐Induced Mitochondrial‐Dependent Cell Death In Fgfr2‐Mutant Endometrial Cancer
  63. Bevacizumab Synergizes With The Bcl-2 Inhibitor Venetoclax To Effectively Treat B‐Cell Non‐Hodgkin’S Lymphoma
  64. Bi-33, A Novel And Potent Pan-Bcl-2 Inhibitor, Induces Apoptosis In Cancer Cells And Shows Combinational Effect With Chemo Drugs
  65. Binding Of A Bcl-2 Family Inhibitor To Bovine Serum Albumin: Fluorescence Quenching And Molecular Docking Study
  66. Bortezomib Induces Oxidative Stress And Apoptosis That Are Synergistically Enhanced By A Bcl-2 Inhibitor In Human Pancreatic Cancer Cells
  67. Breast Cancer Cells Can Evade Apoptosis-Mediated Selective Killing By A Novel Small Molecule Inhibitor Of Bcl-2
  68. Chemoresistance To Concanamycin A1 In Human Oral Squamous Cell Carcinoma Is Attenuated By An Hdac Inhibitor Partly Via Suppression Of Bcl-2 Expression
  69. Clinical Experience With The Bcl-2‐Inhibitor Venetoclax In Combination Therapy For Relapsed And Refractory Acute Myeloid Leukemia And Related Myeloid Malignancies
  70. Co-Administration Of The Mtorc1/Torc2 Inhibitor Ink128 And The Bcl-2/Bcl-Xl Antagonist Abt-737 Kills Human Myeloid Leukemia Cells Through Mcl-1 Down …
  71. Combination Bcl-2 Inhibitor Therapy With Venetoclax And Navitoclax In Patients With Relapsed/Refractory Acute Lymphoblastic …
  72. Combination Of Guanine Arabinoside And Bcl‐2 Inhibitor Yc 137 Overcomes The Cytarabine Resistance In Hl‐60 Leukemia Cell Line
  73. Combination Of The Glycoengineered Type Ii Cd20 Antibody Obinutuzumab (Ga101) And The Novel Bcl-2 Selective Inhibitor Gdc-0199 Results In Superior In Vitro And …
  74. Combining A Gsi And Bcl-2 Inhibitor To Overcome Melanoma’S Resistance To Current Treatments
  75. Critical Upstream Signals Of Cytochrome C Release Induced By A Novel Bcl-2 Inhibitor
  76. Cycling1 Amplification Enhances Aurora Kinase Inhibitor-Induced Polyploid Resistance And Inhibition Of Bcl-2 Pathway Reverses The Resistance
  77. Deletion Of The Innate Immune Nlrp3 Receptor Abolishes Cardiac Ischemic Preconditioning And Is Associated With Decreased Il-6/Stat3 Signaling
  78. Development Of A Convergent Large-Scale Synthesis For Venetoclax, A First-In-Class Bcl-2 Selective Inhibitor
  79. Dipg-62. Carboplatin Synergizes With Bcl-2 Inhibitor To Potentiate Killing Of Dipg Cells
  80. Discovery Of A Potent And Selective Bcl-2 Inhibitor Using Sar By Nmr
  81. Dna Damage Induces The Il-6/Stat3 Signaling Pathway, Which Has Anti-Senescence And Growth-Promoting Functions In Human Tumors
  82. Down-Regulation Of The Apoptosis-Inducing Factor Or Bcl-2 Inhibitor Of Transcription By Rna Interference Can Alleviate Tap63Γ-Induced Apoptosis In Esophageal …
  83. Dysregulated Mir-124 And Mir-200 Expression Contribute To Cholangiocyte Proliferation In The Cholestatic Liver By Targeting Il-6/Stat3 Signalling
  84. Early Data Promising For Pan-Bcl-2 Inhibitor In Hematologic Malignancies
  85. Effect Of A Small Molecule Bcl‐2 Inhibitor On Immune Function And Use With A Recombinant Vaccine
  86. Effect Of Ketoconazole, A Strong Cyp3A Inhibitor, On The Pharmacokinetics Of Venetoclax, A Bcl‐2 Inhibitor, In Patients With Non‐Hodgkin Lymphoma
  87. Effect Of Low‐And High‐Fat Meals On The Pharmacokinetics Of Venetoclax, A Selective First‐In‐Class Bcl‐2 Inhibitor
  88. Effect Of Rifampin On The Pharmacokinetics, Safety And Tolerability Of Navitoclax (Abt‐263), A Dual Inhibitor Of Bcl‐2 And Bcl‐Xl, In Patients With Cancer
  89. Efficacy And Safety Of Bcl-2 Inhibitor Venetoclax In Hematological Malignancy: A Systematic Review And Meta-Analysis Of Clinical Trials
  90. Efficacy Of The Pan-Bcl-2 Inhibitor (Obatoclax) As A Single Agent To Treat Myeloproliferative Neoplasm In Jak2V617F Murine Transplantation Model
  91. Elevated Expression Of S100A8 And S100A9 Correlates With Resistance To The Bcl-2 Inhibitor Venetoclax In Aml
  92. Embelin Reduces Colitis-Associated Tumorigenesis Through Limiting Il-6/Stat3 Signaling
  93. Epigenetic Alterations In Cholangiocarcinoma-Sustained Il-6/Stat3 Signaling In Cholangio-Carcinoma Due To Socs3 Epigenetic Silencing
  94. Evaluation Of Rifampin’S Transporter Inhibitory And Cyp3A Inductive Effects On The Pharmacokinetics Of Venetoclax, A Bcl‐2 Inhibitor: Results Of A Single‐And Multiple …
  95. Evaluation Of The Bcl-2 Inhibitor Abt-199 In Xenograft Models Of Acute Lymphoblastic Leukemia By The Pediatric Preclinical Testing Program
  96. Exploring The Selectivity Of Inhibitor Complexes With Bcl-2 And Bcl-Xl: A Molecular Dynamics Simulation Approach
  97. Exposure-Response Analyses Of The Effects Of Venetoclax, A Selective Bcl-2 Inhibitor, On B-Lymphocyte And Total Lymphocyte Counts In Women With Systemic …
  98. Extended Phase I Trial Of The Oral Pan-Bcl-2 Inhibitor At-101 By Multiple Dosing Schedules In Patients With Advanced Cancers
  99. Fcn-338, A Novel And Selective Bcl-2 Inhibitor, Exhibits Potent Anti-Tumor Activity In B-Cell Lymphoma
  100. Fenretinide Via Noxa Induction, Enhanced Activity Of The Bcl-2 Inhibitor Venetoclax In High Bcl-2–Expressing Neuroblastoma Preclinical Models
  101. Genomic Analysis Of Small-Cell Lung Carcinomas: Discovery Of A Candidate Stratification Biomarker For A Bcl-2 Inhibitor
  102. Gx15–070 (Obatoclax), A Bcl-2 Family Proteins Inhibitor Engenders Apoptosis And Pro-Survival Autophagy And Increases Chemosensitivity In Neuroblastoma
  103. Hematologic Tumor Cell Resistance To The Bcl-2 Inhibitor Venetoclax: A Product Of Its Microenvironment?
  104. Hepatic Acute Phase Proteins–Regulation By Il-6-And Il-1-Type Cytokines Involving Stat3 And Its Crosstalk With Nf-Κb-Dependent Signaling
  105. Hmgb1-Il-23-Il-17-Il-6-Stat3 Axis Promotes Tumor Growth In Murine Models Of Melanoma
  106. Hsp90 Inhibitor (Nvp-Auy922) Enhances Anti-Cancer Effect Of Bcl-2 Inhibitor (Abt-737) In Small Cell Lung Cancer
  107. Hsp90 Inhibitor (Nvp-Auy922) Enhances The Anti-Cancer Effect Of Bcl-2 Inhibitor (Abt-737) In Small Cell Lung Cancer Expressing Bcl-2
  108. Ibrutinib Combined With Car-T Cells In The Treatment Of Del (17P) Chronic Lymphocytic Leukemia With Bcl-2 Inhibitor Resistance: A Case Report And Literature Review
  109. Identification Of A Novel Bcl-2 Inhibitor By Ligand-Based Screening And Investigation Of Its Anti-Cancer Effect On Human Breast Cancer Cells
  110. Il-17 Induces Akt-Dependent Il-6/Jak2/Stat3 Activation And Tumor Progression In Hepatocellular Carcinoma
  111. Il-6 Promotes Head And Neck Tumor Metastasis By Inducing Epithelial–Mesenchymal Transition Via The Jak-Stat3-Snail Signaling Pathway
  112. Il-6 Trans-Signaling Modulates Tlr4-Dependent Inflammatory Responses Via Stat3
  113. Il-6 Trans-Signaling Via Stat3 Directs T Cell Infiltration In Acute Inflammation
  114. Il-6–Gp130–Stat3 In T Cells Directs The Development Of Il-17+ Th With A Minimum Effect On That Of Treg In The Steady State
  115. Il-6/Stat3/Tff3 Signaling Regulates Human Biliary Epithelial Cell Migration And Wound Healing In Vitro
  116. Immunosensitization With A Bcl-2 Small Molecule Inhibitor
  117. Immunotoxin And Bcl-2 Inhibitor Combination Therapy Targeting Chondroitin Sulfate Proteoglycan 4.
  118. Implantation Of Bone Marrow Mesenchymal Stem Cells Inhibits Bcl-2 And Bax-Mediated Neuronal Apoptosis In Rats After Cerebral Ischemic Injury
  119. In Vitro Analysis Of Pan-Bcl-2 Inhibitor Gx15-070 (Obatoclax) On Human Lymphocytes For The Feasibility Of Combination Immunotherapy.
  120. In Vivo And In Vitro Inhibition Of Osteosarcoma Growth By The Pan Bcl-2 Inhibitor At-101
  121. In Vivo Efficacy Of At-101, An Orally Active Pan Bcl-2 Family Protein Inhibitor In Combination With Docetaxel Or Erlotinib For Non Small Cell Lung Cancer Therapy
  122. In Vivo Efficacy Of Novel Methionine Aminopeptidase 2 Inhibitors, Alone And In Combination With Clinical Drugs And A Novel Bcl-2 Inhibitor
  123. Inducible Microrna-223 Down-Regulation Promotes Tlr-Triggered Il-6 And Il-1Β Production In Macrophages By Targeting Stat3
  124. Inducing Apoptosis In Mantle Cell Lymphoma Using Inhibitors Of Cyclin-Dependent Kinases And The Bcl-2 Inhibitor Abt-737
  125. Induction Of Neutrophil Apoptosis By A Bcl-2 Inhibitor Reduces Particulate Matter-Induced Lung Inflammation
  126. Induction Of Neutrophil Apoptosis By Bcl-2 Inhibitor Reduces Pm-Induced Airway Inflammation
  127. Inhibiting Mitochondria Function By Bcl-2 Inhibitor Venetoclax And Complex I Inhibitor Iacs-010759 Eliminate Leukemia Cells In Pre-Clinical Aml Models
  128. Inhibition Of Chk1 Enhances Cell Death Induced By The Bcl-2-Selective Inhibitor Abt-199 In Acute Myeloid Leukemia Cells
  129. Inhibition Of Growth Of Human Breast Cancer Cell Lines With The Combination Of An Egfr/Her-2/Neu Tyrosine Kinase Inhibitor And A Bcl-2 Inhibitor
  130. Inhibition Of Growth Of Human Breast Cancer Cell Lines With The Combination Of An Mtor Inhibitor And A Bcl-2 Inhibitor
  131. Inhibition Of Il-6/Stat3 Axis And Targeting Axl And Tyro3 Receptor Tyrosine Kinases By Apigenin Circumvent Taxol Resistance In Ovarian Cancer Cells
  132. Inhibition Of Stat3 Signaling Blocks The Anti-Apoptotic Activity Of Il-6 In Human Liver Cancer Cells
  133. Interaction Studies To Evaluate 2-Carboxyphenolate Analogues As Inhibitor Of Anti-Apoptotic Protein Bcl-2
  134. Interim Results From A Dose-Escalation Study Of The Bcl-2 Inhibitor Venetoclax (Abt-199/Gdc-0199) Plus Bendamustine (B) And Rituximab (R) In Patients (Pts) With …
  135. Jak/Stat3 Pathway Inhibition Blocks Skeletal Muscle Wasting Downstream Of Il-6 And In Experimental Cancer Cachexia
  136. Lipopolysaccharides Upregulate Hepcidin In Neuron Via Microglia And The Il-6/Stat3 Signaling Pathway
  137. Lps And Tnfα Induce Socs3 Mrna And Inhibit Il‐6‐Induced Activation Of Stat3 In Macrophages
  138. Mcl-1 And Bcl-Xl-Dependent Resistance To The Bcl-2 Inhibitor Abt-199 Can Be Overcome By Preventing Pi3K/Akt/Mtor Activation In Lymphoid …
  139. Mcl-1 And Fbw7 Control A Dominant Survival Pathway Underlying Hdac And Bcl-2 Inhibitor Synergy In Squamous Cell Carcinoma
  140. Mcl-1 Inhibitor-Induced Killing Of Multiple Myeloma Is Modulated By The Relative Level Of Expression Of Pro-Survival Members Of The Bcl-2 Family And The Proto …
  141. Mcl-1 Or Bcl-Xl-Dependent Resistance To The Bcl-2 Antagonist (Abt-199) Can Be Overcome By Specific Inhibitor As Single Agents And In Combination With Abt-199 In …
  142. Mcl-1 Up-Regulation Through Mapk Activation Confers Acquired Resistance To Bcl-2 Inhibitor Abt-199 In Pre-Clinical Aml Models
  143. Metabolic Changes Associated With Metformin Potentiates Bcl-2 Inhibitor, Venetoclax, And Cdk9 Inhibitor, Bay1143572 And Reduces Viability Of Lymphoma …
  144. Metformin Synergizes With Bcl-Xl/Bcl-2 Inhibitor Abt-263 To Induce Apoptosis Specifically In P53-Defective Cancer Cells
  145. Metronomic Small Molecule Inhibitor Of Bcl-2 (Tw-37) Is Antiangiogenic And Potentiates The Antitumor Effect Of Ionizing Radiation
  146. Mik665/S64315, A Novel Mcl-1 Inhibitor, In Combination With Bcl-2 Inhibitors Exhibits Strong Synergistic Antitumor Activity In A Range Of Hematologic Malignancies
  147. Mir-143 Is Downregulated In Cervical Cancer And Promotes Apoptosis And Inhibits Tumor Formation By Targeting Bcl-2
  148. Mir-17-92 Cluster Promotes Cholangiocarcinoma Growth: Evidence For Pten As Downstream Target And Il-6/Stat3 As Upstream Activator
  149. Mir-1915-3P Inhibits Bcl-2 Expression In The Development Of Gastric Cancer
  150. Mir‐1915 Inhibits Bcl‐2 To Modulate Multidrug Resistance By Increasing Drug‐Sensitivity In Human Colorectal Carcinoma Cells
  151. Mitochondrial Targeting By Use Of Lipid Nanocapsules Loaded With Sv30, An Analogue Of The Small-Molecule Bcl-2 Inhibitor Ha14-1
  152. Molecular Dynamic Simulations On An Inhibitor Of Anti-Apoptotic Bcl-2 Proteins For Insights Into Its Interaction Mechanism For Anti-Cancer Activity
  153. N-(3-Oxo-Acyl) Homoserine Lactone Inhibits Tumor Growth Independent Of Bcl-2 Proteins
  154. N′-((2-(6-Bromo-2-Oxo-2H-Chromen-3-Yl)-1H-Indol-3-Yl) Methylene) Benzohydrazide As A Probable Bcl-2/Bcl-Xl Inhibitor With Apoptotic And Anti-Metastatic Potential
  155. Naringenin-Induced Apoptosis Is Attenuated By Bcl-2 But Restored By The Small Molecule Bcl-2 Inhibitor, Ha 14-1, In Human Leukemia U937 Cells
  156. Navitoclax, A Targeted High-Affinity Inhibitor Of Bcl-2, In Lymphoid Malignancies: A Phase 1 Dose-Escalation Study Of Safety, Pharmacokinetics, Pharmacodynamics, And …
  157. Non-Cell-Autonomous Activation Of Il-6/Stat3 Signaling Mediates Fgf19-Driven Hepatocarcinogenesis
  158. Obatoclax, A Pan-Bcl-2 Inhibitor, Targets Cyclin D1 For Degradation To Induce Antiproliferation In Human Colorectal Carcinoma Cells
  159. Oocyte-Secreted Growth Differentiation Factor 9 Inhibits Bcl-2-Interacting Mediator Of Cell Death-Extra Long Expression In Porcine Cumulus Cell
  160. Overcoming Resistance To Ac0010, A Third Generation Of Egfr Inhibitor, By Targeting C-Met And Bcl-2
  161. Overcoming The Radioresistance Of Prostate Cancer Cells With A Novel Bcl-2 Inhibitor
  162. P53-Dependent Regulation Of Mcl-1 Contributes To Synergistic Cell Death By Ionizing Radiation And The Bcl-2/Bcl-Xl Inhibitor Abt-737
  163. Pan-Bcl-2 Inhibitor At-101 Enhances Tumor Cell Killing By Egfr Targeted T Cells
  164. Pan-Bcl-2 Inhibitor, Gx15-070 (Obatoclax), Decreases Human T Regulatory Lymphocytes While Preserving Effector T Lymphocytes: A Rationale For Its Use In Combination …
  165. Pediatric Preclinical Testing Program (Pptp) Evaluation Of The Bcl-2 Inhibitor Abt-263
  166. Pharmacokinetics Of The B-Cell Lymphoma 2 (Bcl-2) Inhibitor Venetoclax In Female Subjects With Systemic Lupus Erythematosus
  167. Pharmacokinetics Of The Bcl-2 Inhibitor Venetoclax In Subjects With Hepatic Impairment
  168. Pharmacokinetics Of The Bcl‐2 Inhibitor Venetoclax In Healthy Chinese Subjects
  169. Pharmacokinetics Of Venetoclax, A Novel Bcl‐2 Inhibitor, In Patients With Relapsed Or Refractory Chronic Lymphocytic Leukemia Or Non‐Hodgkin Lymphoma
  170. Phase 1 Study Of The Safety, Pharmacokinetics, And Antitumour Activity Of The Bcl-2 Inhibitor Navitoclax In Combination With Rituximab In Patients With Relapsed Or …
  171. Phase I Study Of A Novel Bcl-2 Inhibitor, At-101 In Combination With Lenalidomide And Dexamethasone In Patients With Relapsed And/Or Refractory Multiple Myeloma …
  172. Phase I Trial Of Escalating Doses Of The Bcl-2 Inhibitor Venetoclax In Combination With Daunorubicin/Cytarabine Induction And High Dose Cytarabine Consolidation In …
  173. Pmca2 Silencing Potentiates Mda-Mb-231 Breast Cancer Cell Death Initiated With The Bcl-2 Inhibitor Abt-263
  174. Potential Utility Of The Pan-Bcl-2 Inhibitor Gx15–070 (Obatoclax) In Cancer Immunotherapy
  175. Pre-Clinical Evaluation Of Bcl-2 Inhibitor Abt-737 In Small Cell Lung Cancer
  176. Preclinical Evaluation Of Apoptosis Induction By The Novel Small Molecule Bcl-2 Inhibitor, Gx015–070, In Ex Vivo Chronic Lymphoid Leukemia (Cll) Cells
  177. Preclinical Study Of A Bcl-2 Inhibitor In Neuroblastoma.
  178. Prediction Of Human Nonlinear Pharmacokinetics Of A New Bcl-2 Inhibitor Using Pbpk Modeling And Interspecies Extrapolation Strategy
  179. Promise Of Combining A Bcl-2 Family Inhibitor With Bortezomib Or Saha For Adult T-Cell Leukemia/Lymphoma
  180. Rac1 Mediates Stat3 Activation By Autocrine Il-6
  181. Radiosensitization By A Novel Bcl-2 And Bcl-Xl Inhibitor S44563 In Small-Cell Lung Cancer
  182. Rapid Complete Response To Single-Agent Bcl-2 Inhibitor Venetoclax In A Heart-Transplanted Patient With Triple Refractory Immunoglobulin Light-Chain Amyloidosis
  183. Ras Blockade Inhibits Bcl-2 Modifying Factor (Bmf) Expression And Prevents Hypertension And Tubular Apoptosis In Diabetic Akita Mouse Kidneys
  184. Removed: Molecular Mechanisms Involved In Resistance Of Cll Cells Towards Abt-737, A Specific Bcl-2 Inhibitor
  185. Rnai Inhibits Bcl-2 Gene Expression And Enhances Radio-Sensitivity Of Lung Adenocarcinoma Cell Line A549.
  186. S55746 Is A Novel Orally Active Bcl-2 Selective And Potent Inhibitor That Impairs Hematological Tumor Growth
  187. Safety, Pharmacokinetics, Pharmacodynamics, And Activity Of Navitoclax, A Targeted High Affinity Inhibitor Of Bcl-2, In Lymphoid Malignancies
  188. Selective Bcl-2 Inhibitor Probes
  189. Ser727‐Dependent Transcriptional Activation By Association Of P300 With Stat3 Upon Il‐6 Stimulation
  190. Small Molecule Bcl-2 Inhibitor Enhances Apoptosis Induction By Gemcitabine Or Sulindac Sulfide In Bxpc-3 Pancreatic Cancer Cells
  191. Small Molecule Pan-Bcl-2 Inhibitor At-101 Induces Apoptosis In Nsclc By Up-Regulating Noxa And Enhances Antitumor Activity Of Docetaxel Or Targeted Kinase …
  192. Small-Molecule Bh3 Mimetic And Pan-Bcl-2 Inhibitor At-101 Enhances The Antitumor Efficacy Of Cisplatin Through Inhibition Of Ape1 Repair And Redox Activity In …
  193. Stat3 Activation By Il-6 From Mesenchymal Stem Cells Promotes The Proliferation And Metastasis Of Osteosarcoma
  194. Stat3 Activation In Response To Il-6 Is Prolonged By The Binding Of Il-6 Receptor To Egf Receptor
  195. Stat3 Mediates Il‐6‐Induced Neuroendocrine Differentiation In Prostate Cancer Cells
  196. Statins Enhance Killing Of Multiple Myeloma Cells By The Bcl-2 Inhibitor Venetoclax And The Mcl-1 Inhibitor S63845
  197. Sulindac Sulfide–Induced Apoptosis Is Enhanced By A Small-Molecule Bcl-2 Inhibitor And By Trail In Human Colon Cancer Cells Overexpressing Bcl-2
  198. Survivin Inhibition Is Critical For Bcl-2 Family Inhibitor, Abt-263 To Induce Apoptosis In Liver Cancer Cells
  199. Survivin Inhibition Is Critical For Bcl-2 Inhibitor-Induced Apoptosis In Hepatocellular Carcinoma Cells
  200. Synergistic Aml Cell Death Induction By Marine Cytotoxin (+)-1 (R), 6 (S), 1′(R), 6′(S), 11 (R), 17 (S)-Fistularin-3 And Bcl-2 Inhibitor Venetoclax
  201. Synergistic Combination Of Small Molecule Inhibitor And Rna Interference Against Antiapoptotic Bcl-2 Protein In Head And Neck Cancer Cells
  202. Synergistic Effect Of Bcl-2 Inhibitor Apg-2575 And Cdk9 Inhibitor In Acute Myeloid Leukemia And Dlbcl Preclinical Tumor Models
  203. Synergistic Growth Inhibition Of Human Cancer Cells With Atrasentan And A Bcl-2 Inhibitor
  204. Synergistic Induction Of Apoptosis By The Bcl-2 Inhibitor Abt-737 And Imatinib Mesylate In Gastrointestinal Stromal Tumor Cells
  205. Synergistic Inhibition Of Breast Cancer Cell Lines With A Dual Inhibitor Of Egfr-Her-2/Neu And A Bcl-2 Inhibitor
  206. Synergistic Inhibition Of Breast Cancer Cell Lines With The Combination Of A Dual Inhibitor Of Egfr/Her-2/Neu And A Bcl-2 Inhibitor
  207. Synergistic Inhibition Of Tumor Growth By Combined Treatment With The Pan Bcl-2 Inhibitor At-101 And Docetaxel In Human Cancer Xenograft Models
  208. Systemic Inhibition Of Il-6/Stat3 Signalling Protects Against Experimental Osteoarthritis
  209. Tanshinone Iia Inhibits Breast Cancer Stem Cells Growth In Vitro And In Vivo Through Attenuation Of Il‐6/Stat3/Nf‐Kb Signaling Pathways
  210. Targeted Therapies For Epithelial Cancers: In Vivo Efficacy Of The Bcl-2/Bcl-Xl Inhibitor 2-Meaa
  211. Targeted Therapy With A Selective Bcl-2 Inhibitor In Older Patients With Acute Myeloid Leukemia
  212. Targeting 14-3-3 Sensitizes Native And Mutant Bcr-Abl To Inhibition With U0126, Rapamycin And Bcl-2 Inhibitor Gx15-070
  213. Targeting Aml Through Apoptosis Activation Using Bcl-2/Mcl-1 Or Bcl-2/Hdm2 Inhibitor Combination Therapies
  214. Targeting Apoptosis And Autophagy By A Novel Bcl-2 Inhibitor, Gx15-070, In Neuroblastoma.
  215. Targeting Bcl-2 Overexpression In Various Human Malignancies Through Nf-Κb Inhibition By The Proteasome Inhibitor Bortezomib
  216. Targeting The Il-6/Jak/Stat3 Signalling Axis In Cancer
  217. Telomerase Inhibitor Imetelstat In Combination With The Bcl-2 Inhibitor Venetoclax Enhances Apoptosis In Vitro And Increases Survival In Vivo In Acute Myeloid …
  218. The Bcl-2 Inhibitor Abt-199 Enhances Imatinib-Induced Cell Death In Chronic Phase Cml Progenitors
  219. The Bcl-2 Inhibitor Abt-263 Enhances The Response Of Multiple Chemotherapeutic Regimens In Hematologic Tumors In Vivo
  220. The Bcl-2 Inhibitor Abt-737 Shows Significant Anti-Tumor Efficacy In A Model Of Non-Hodgkin’S B Cell Lymphoma
  221. The Bcl-2/Bcl-Xl Inhibitor Abt-737 Promotes Death Of Retinoblastoma Cancer Cells
  222. The Bcl-2/Bcl-Xl Inhibitor Bh3I-2′ Affects The Dynamics And Subcellular Localization Of Sumoylated Proteins
  223. The Bcl‐2 Inhibitor Venetoclax Inhibits Nrf2 Antioxidant Pathway Activation Induced By Hypomethylating Agents In Aml
  224. The Combination Of A Sphingosine Kinase 2 Inhibitor (Abc294640) And A Bcl‐2 Inhibitor (Abt‐199) Displays Synergistic Anti‐Myeloma Effects In Myeloma Cells Without …
  225. The Cxcr4 Inhibitor Bl-8040 Induces The Apoptosis Of Aml Blasts By Downregulating Erk, Bcl-2, Mcl-1 And Cyclin-D1 Via Altered Mir-15A/16-1 Expression
  226. The Deubiquitinating Enzyme Inhibitor Pr-619 Enhances The Cytotoxicity Of Cisplatin Via The Suppression Of Anti-Apoptotic Bcl-2 Protein: In Vitro And In Vivo Study
  227. The Discovery Of Navitoclax, A Bcl-2 Family Inhibitor
  228. The Dual Pi3K-Δ/Γ Inhibitor Duvelisib In Combination With The Bcl-2 Inhibitor Venetoclax Shows Promising Responses In Richter Syndrome-Pdx Models
  229. The Ewing Family Of Tumors Relies On Bcl-2 And Bcl-Xl To Escape Parp Inhibitor Toxicity
  230. The Il-6–Stat3 Axis Mediates A Reciprocal Crosstalk Between Cancer-Derived Mesenchymal Stem Cells And Neutrophils To Synergistically Prompt Gastric …
  231. The Il-6/Gp130/Stat3 Signaling Axis: Recent Advances Towards Specific Inhibition
  232. The Il-6/Jak/Stat3 Pathway: Potential Therapeutic Strategies In Treating Colorectal Cancer
  233. The Irreversible Erbb1/2/4 Inhibitor Neratinib Interacts With The Bcl-2 Inhibitor Venetoclax To Kill Mammary Cancer Cells
  234. The Novel Antisense Bcl-2 Inhibitor Spc2996 Causes Rapid Leukemic Cell Clearance And Immune Activation In Chronic Lymphocytic Leukemia
  235. The Novel Imipridone Onc212 Highly Synergizes With The Bcl-2 Inhibitor Abt-199 In Aml And Activates Orphan Receptor Gpr132
  236. The Pan-Bcl-2 Inhibitor (−)-Gossypol Triggers Autophagic Cell Death In Malignant Glioma
  237. The Proteasome Inhibitor Bortezomib Promotes Mitochondrial Injury And Apoptosis Induced By The Small Molecule Bcl-2 Inhibitor Ha14-1 In Multiple Myeloma Cells
  238. The Selective Bcl-2 Inhibitor Abt-199 Induces Cell Death Via The Intrinsic Apoptotic Pathway In Canine B-Cell And T-Cell Lymphoma Cell Lines
  239. The Sensitivity Of Diffuse Large B-Cell Lymphoma Cell Lines To Histone Deacetylase Inhibitor-Induced Apoptosis Is Modulated By Bcl-2 Family Protein Activity
  240. The Small Molecule Bcl-2 Inhibitor Ha14-1 Interacts Synergistically With Flavopiridol To Induce Mitochondrial Injury And Apoptosis In Human Myeloma Cells Through A …
  241. The Small Molecule Bcl-2 Inhibitor Ha14-1 Potentiates The Lethality Of A Regimen Combining Mek1/2 And Chk1 Inhibitors In Multiple Myeloma Cells
  242. The Small Molecule Bcl-2/Mcl-1 Inhibitor Tw-37 Shows Single-Agent Cytotoxicity In Neuroblastoma Cell Lines
  243. The Small Molecule Pan-Bcl-2 Inhibitor Gx15-070 Induces Apoptosis In Vitro In Mantle Cell Lymphoma (Mcl) Cells And Exhibits A Synergistic Effect In Combination With …
  244. The Small-Molecule Bcl-2 Inhibitor Ha14-1 Interacts Synergistically With Flavopiridol To Induce Mitochondrial Injury And Apoptosis In Human Myeloma Cells Through A …
  245. The Use Of The Bcl-2 Inhibitor In Cll Patients Who Progressed After B-Cell-Receptor Inhibitors: A Retrospective Multicenter …
  246. Therapeutic Efficacy Of Abt-737, A Bcl-2 Inhibitor, In A Canine Melanoma Cell Line
  247. Therapeutic Silencing Of Bcl-2 By Systemically Administered Sirna Nanotherapeutics Inhibits Tumor Growth By Autophagy And Apoptosis And Enhances The …
  248. Therapeutic Targeting Of Il-6 Trans Signaling Counteracts Stat3 Control Of Experimental Inflammatory Arthritis
  249. Thu0282 Exposure-Response Analyses Of Effects Of Venetoclax, A Selective Bcl-2 Inhibitor, On B And Total Lymphocyte Counts In Female Subjects With Systemic …
  250. Thu0306 Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of The Bcl-2 Inhibitor Venetoclax (Abt-199) In A Phase 1 Single And Multiple Ascending …
  251. Thu0382 Venetoclax (Abt-199), A Potent And Selective Bcl-2 Inhibitor, Prevents Nephritis In Lupus Prone Nzb/W F1 Mice By Depleting Selective Lymphocyte …
  252. To Overcoming Rituximab-Chemotherapy Resistance By Targeting The Autophagy Pathway Using Bortezomib In Combination With The Bcl-2 Inhibitor Obatoclax In Non …
  253. Transcriptional Inactivation Of Stat3 By Pparγ Suppresses Il-6-Responsive Multiple Myeloma Cells
  254. Tumor Growth Inhibition Modelling Based On Receptor Occupancy And Biomarker Activity Of A New Bcl-2 Inhibitor In Mice
  255. Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand–Induced Apoptosis Is Inhibited By Bcl-2 But Restored By The Small Molecule Bcl-2 Inhibitor, Ha 14-1, In …
  256. Tw-37, A Nonpeptidic Small-Molecule Inhibitor Of Bcl-2, Inhibits Cell Invasion And Angiogenesis In Pancreatic Cancer
  257. Updated Results Of A Phase I First-In-Human Study Of The Bcl-2 Inhibitor Abt-199 (Gdc-0199) In Patients With Relapsed/Refractory Non-Hodgkin Lymphoma (Nhl).
  258. Venclexta (Venetoclax) First Bcl-2 Inhibitor Approved For High-Risk Relapsed Chronic Lymphocytic Leukemia
  259. Venetoclax (Abt-199), A Potent And Selective Bcl-2 Inhibitor, Is Efficacious In Nzb/Wf1 Mouse Model Of Lupus Nephritis And Reduces Human Lymphocyte Lifespan In …
  260. Venetoclax, A Novel Bcl-2 Inhibitor, Induces Cell Growth Suppression, Apoptosis, Cell Cycle Arrest, And Autophagy In Triple Negative Breast Cancer Mda-Mb-231 …
  261. Vesicular Stomatitis Virus And Bcl-2 Inhibitor Combination Therapy For The Treatment Of Chronic Lymphocytic Leukemia
  262. Virtual Screening, Sar, And Discovery Of 5‐(Indole‐3‐Yl)‐2‐[(2‐Nitrophenyl) Amino][1, 3, 4]‐Oxadiazole As A Novel Bcl‐2 Inhibitor
  263. Vsv Oncolysis In Combination With The Bcl-2 Inhibitor Obatoclax Overcomes Apoptosis Resistance In Chronic Lymphocytic Leukemia
Related Posts

Conditioned Place Preference

BCL-XL

Ramadan

Mandatory FDA Disclaimer: Not intended to diagnose, treat, cure or prevent any disease.

Mandatory FDA Disclaimer: Not intended to diagnose, treat, cure or prevent any disease.

0
    0
    Your Cart
    Your cart is emptyReturn to Shop
    Continue Shopping